Navigation Links
Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Date:9/5/2007

NicVAX Supports Statistically Significant Point Prevalence and Continuous Abstinence by Dose, Schedule and Antibody Response; Nabi to Host Conference

Call Today

BOCA RATON, Fla., Sept. 5 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced nine-month data from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. These nine-month data demonstrate NicVAX efficacy in supporting statistically significant and continuous abstinence rates by dose as well as by antibody response. The nine-month data also have enabled Nabi to determine what it believes is the most effective dose and schedule for NicVAX and determine the antibody concentration threshold for clinical efficacy. In May 2007, Nabi announced this trial's six-month data -- a statistically significant number of patients with a high anti-nicotine antibody response met the trial's primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

NicVAX Nine-Month Data Key Findings

-- High antibody responders (top 30%) continued to show statistically

significant abstinence at nine months:

-- 9-Month continuous abstinence rate: NicVAX=20% (12/61, p=0.0076) vs.

Placebo=6% (6/100)

-- Statistically significant dose response observed for continuous

abstinence at six and nine months for Schedule 2, 200 and 400 microgram

doses in the intent to treat population:

-- 9-Month continuous abstinence: NicVAX 400 micrograms =18% (9/51,

p=0.0047), Placebo=4% (4/100)

-- 9-
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ts for Spinal Cord, Other Nerve,Injuries -, PHILA...in that enables,nerve cells to communicate with ea...oping nervous system. Research into how that prote...ells may provide a basis for eventual,treatments f...ystem,including spinal cord injury., "This expan...
(Date:10/8/2008)...-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. 8 /PRNe...poration (TSX: NVN) today presented positive data ...l-like Receptor 3 agonist, Poly IC-Poly,Arginine (...yon, France.,Study results demonstrated Poly-ICR t...like Receptor 3 (TLR3) pathway. Data showed that,P...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...all/ -- CEL-SCI Corporation,(NYSE: CVM ) announce...er,Agreement (MTA) with the National Institutes of... of Dr. Francesco M. Marincola, M.D., to,investiga...roenvironment,caused by CEL-SCI,s cancer drug Mult...s Disease and Immunogentics Section, Department of...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Mom You Rock 21 17145 1What You Dont Know Could Hurt You 17142 1What You Dont Know Could Hurt You 17142 2What You Dont Know Could Hurt You 17142 3Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 1Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 2Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 3Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 1Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 2
...oupe Francophone du Myelome (IFM),Trial Presented ...ewswire-FirstCall/ --,Millennium Pharmaceuticals, ...n the comparative Phase III clinical trial evaluat...tiple myeloma (MM),patients. As induction therapy ...ADE based therapy produced a high complete remissi...
...Ablynx today announced positive,interim results fr...nt programme, ALX-0081, an anti-thrombotic treatme...e; therapeutic,Nanobody® targeting von Willebr...ombosis in patients with acute coronary,syndrome. ...ned to assess,safety, tolerability and pharmacokin...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...led that the way a baby girl develops in a womb ma...tic ovarian syndrome (PCO) as adults. Dr Michael D... Reproductive Health at the University of Adelaide... team studied a group of young women bon between 1...
... that the incidence of leukemia and infections in ...ls. Stem cells are undifferentiated cells that ha...into all types of specialized cells types that may...s of the tissue from which it was taken. Researche...
...ecent study researchers say that a diet rich in ca..., cheese, yogurt and fortified orange juice can ac...al Syndrome (PMS) symptoms. Studies in the past ha...ope with PMS, however more recent studies suggest ...
...chizophrenic patients with the help of seroquel is... chronic severe disabling mental illness. Some of ...nations seen or heard, feelings of being persecute...havior. Schizophrenia can be treated symptomatical...
Other Medicine News:Health News:Developmental Origins of Polycystic Ovarian Syndrome 2
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates. 250 sheet roll.
Inquire
Top cover cold rolled steel with stove enamel coated (RAL 7035 grey) Work surface polyethylene Front, back and side windows 6 mm tempered glass 3 UV lamps Internal adjustable tempered gl
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)
Medicine Products: